A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial intelligence ...
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Doctors have long been hamstrung in their efforts to help ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why. Researchers found that inflammation in the brain disrupts the energy supply of ...
Summary: A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis. Researchers discovered that a high ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Lipoic acid (LA), an oral antioxidant supplement, was not associated with greater improvements in timed walking speed or other clinical outcomes in patients with progressive multiple sclerosis (MS) ...
A study from Sweden’s Uppsala University discovered a link between microplastics and multiple sclerosis (MS). The research, published in the journal Environmental International, discovered that ...
Selma Blair is grateful to be feeling good. The Cruel Intentions star, who shared her multiple sclerosis (MS) diagnosis in 2018, offered a positive update on her health, revealing that she’s been ...
Selma Blair shared an update on her battle with multiple sclerosis (MS), more than seven years after revealing her diagnosis. Speaking to Stellar on Saturday, November 22, Blair, 53, confirmed she had ...
Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, cutting the number of relapses compared to another treatment over nearly ...
Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.
MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower MS prevalence. High-titer MOG-IgG results confirm MOGAD, but low-titer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results